Breaking News Instant updates and real-time market news.

APHA

Aphria

$6.58

-0.33 (-4.78%)

, FTR

Frontier Communications

$1.86

-0.03 (-1.59%)

08:45
06/03/19
06/03
08:45
06/03/19
08:45

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Aphria (APHA) 40.95% +9.34, Frontier Communications (FTR) 46.57% +0.30, Maxar Technologies (MAXR) 2.63% +0.27, AutoZone (AZO) 0.38% +0.13, Pennsylvania REIT (PEI) 4.56% +0.12, ProShares VIX Short Term Futures (VIXY) 4.90% +0.10, iShares iBoxx Dollar High Yield Corporate Bond Fund (HYG) 1.53% +0.05, Direxion Daily Semiconductor Bear 3X Shares (SOXS) 5.55% +0.03, ConAgra (CAG) 0.28% +0.03, and Zynerba (ZYNE) 17.11% +0.01.

APHA

Aphria

$6.58

-0.33 (-4.78%)

FTR

Frontier Communications

$1.86

-0.03 (-1.59%)

MAXR

Maxar Technologies

$6.76

-0.28 (-3.98%)

AZO

AutoZone

$1,026.21

-18.305 (-1.75%)

PEI

Pennsylvania REIT

$6.42

-0.005 (-0.08%)

HYG

iShares iBoxx $ High Yield Corporate Bond

$84.94

-0.57 (-0.67%)

CAG

Conagra Brands

$26.78

-0.09 (-0.33%)

ZYNE

Zynerba

$12.35

-0.26 (-2.06%)

  • 04

    Jun

  • 04

    Jun

  • 06

    Jun

  • 11

    Jun

  • 18

    Jun

APHA Aphria
$6.58

-0.33 (-4.78%)

04/16/19
VERF
04/16/19
NO CHANGE
Target $8
VERF
Sell
Use Aphria results as guide and short Tilray shares, says Vertical Group
Vertical Group analyst Gordon Johnson tells investors to use Aphria's (APHA) fiscal Q3 results as a guide and build a short position in Tilray (TLRY). The analyst last week initiated coverage of Tilray with a Sell rating and $8 year-end price target. Despite expectations for growth in Canadian sales due to the growth expectations for the recreational cannabis market, Aphria's kilograms sold fell 22.7% quarter-over-quarter in the quarter reported yesterday, Johnson tells investors in an email to clients. The analyst maintains his negative bias on Tilray following Aphia's results. Shares of Tilray are up 54c to $49.78 in early trading.
05/24/19
JEFF
05/24/19
INITIATION
JEFF
Buy
Jefferies starts Aphria at Buy, says valuation 'not reflective of reality'
Jefferies analyst Owen Bennett initiated coverage of Aphria (APHA) with a Buy rating and C$15 price target. The stock closed yesterday down 33c to $6.41. The analyst says the company scores highly on his "strategic scorecard," or third overall behind only Canopy Growth (CGC) and Aurora Cannabis (ACB). Despite a "strong global outlook," Aphria's valuation is the cheapest across the space, with allegations around inflated assets/insider deals weighing on the shares, Bennett tells investors in a research note. The analyst expects a "significant re-rating" in the shares with "these issues now seemingly cleared up." He points out that the company's questionable relationships have been severed and a special committee review found assets had not been falsely inflated. Bennett believes Aphria continues to execute and that its valuation is "not reflective of reality."
05/24/19
05/24/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Zoom Video (ZM) initiated with a Perform at Oppenheimer. 2. CannTrust (CTST) initiated with a Buy at BofA/Merrill. 3. Inseego (INSG) initiated with an Outperform at Cowen. 4. Falcon Minerals (FLMN) initiated with an Outperform at Baird. 5. Aphria (APHA) initiated with a Buy at Jefferies. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
03/14/19
COWN
03/14/19
NO CHANGE
COWN
Narrow U.S. cannabis bills have better prospects than broad ones, says Cowen
Cowen analyst Jaret Seiberg said it is hard for him to see a scenario in the 116th Congress in which Senate Majority Leader Mitch McConnell holds a vote on legislation to fully legalize cannabis, as too many senators see no political upside for McConnell to schedule such a vote. Given this view, Seiberg believes that prospects are better for narrower bills that could get attached to spending packages and other measures than for broader bills that would legalize recreational use. Of the narrower bills introduced in the U.S. so far, Seiberg believes the SAFE Act on cannabis banking has the best shot before the 2020 election. Publicly traded companies in the cannabis space include Aphria (APHA), Aurora Cannabis (ACB), CV Sciences (CVSI), CannTrust Holdings (CNTTF), Canopy Growth (CGC), Cronos Group (CRON), General Cannabis (CANN), India Globalization Capital (IGC), MediPharm Labs (MLCPF) and Tilray (TLRY).
FTR Frontier Communications
$1.86

-0.03 (-1.59%)

01/08/19
WELS
01/08/19
DOWNGRADE
Target $1.75
WELS
Underperform
Frontier downgraded to Underperform from Market Perform at Wells Fargo
Wells Fargo analyst Jennifer Fritzsche downgraded Frontier Communications (FTR) to Underperform and lowered her price target for the shares to $1.75 from $5.00. The analyst also downgraded the Rural Local Exchange Carrier sector to Underweight from Market Weight. Frontier has reportedly been working with an advisor on how it might handle upcoming debt maturities, Fritzsche tells investors in a research note. The debt seems to be pricing in a looming restructuring, which "could cause a scar on the RLEC industry," adds the analyst. Fritzsche remains concerned about Frontier's near term balance sheet obligations and believe "this is very much a debt story at this point."
02/19/19
RAJA
02/19/19
DOWNGRADE
RAJA
Market Perform
Frontier Communications downgraded to Market Perform at Raymond James
02/19/19
RAJA
02/19/19
DOWNGRADE
RAJA
Market Perform
Frontier Communications downgraded to Market Perform at Raymond James
Raymond James analyst Frank Louthan downgraded Frontier Communications (FTR) to Market Perform from Outperform saying the negative Windstream (WIN) ruling will have a negative impact from a trading perspective. Louthan said rural ILECs tend to trade as a group and are overly correlated with each other regardless of their results.
01/08/19
WELS
01/08/19
DOWNGRADE
Target $11.25
WELS
Market Perform
Consolidated Communications downgraded to Market Perform at Wells Fargo
Wells Fargo analyst Jennifer Fritzsche downgraded Consolidated Communications to Market Perform from Outperform and lowered her price target for the shares to $11.25 from $13.50. The analyst also downgraded the Rural Local Exchange Carrier sector to Underweight from Market Weight. She believes Consolidated Communications has the ability to sustain its dividend. However, she is concerned that any sort of restructuring, or perception that a restructuring could occur with Frontier Communications (FTR), "could put a stain on the whole RLEC group." If Frontier has to do "some creative things" with its balance sheet, investors will look to who could be next and Consolidated Communications could be on that perceived list, Fritzsche tells investors in a research note.
MAXR Maxar Technologies
$6.76

-0.28 (-3.98%)

03/01/19
CIBC
03/01/19
DOWNGRADE
CIBC
Underperformer
Maxar Technologies downgraded to Underperformer from Neutral at CIBC
03/01/19
TDSI
03/01/19
DOWNGRADE
TDSI
Hold
Maxar Technologies downgraded to Hold from Speculative Buy at TD Securities
03/01/19
03/01/19
DOWNGRADE
Target $9

Hold
Maxar Technologies downgraded to Hold at TD Securities after disappointing Q4
As previously reported, TD Securities analyst Tim James downgraded Maxar Technologies to Hold from Speculative Buy and lowered his price target to $9 from $18.50 after its below-consensus Q4 results. The analyst says his previous constructive thesis attributing the company's weakness to the divestable GEO comsat business was incorrect as the company indicated it will continue to operate it at a loss. James added that the EBITDA of Maxar's Services and Imagery segment was also soft and recommends that investors await for evidence of improvement before considering buying shares again.
03/01/19
03/01/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. L Brands (LB) downgraded to Market Perform from Outperform at Bernstein with analyst Jamie Merriman saying her Outperform rating was based on a view that investors were paying for Bath & Body Works with a free option on Victoria's Secret. 2. American Airlines (AAL) and Delta Air Lines (DAL) downgraded to Hold from Buy at Deutsche Bank. 3. Devon Energy (DVN) downgraded to Sector Perform from Outperform at RBC Capital. 4. O'Reilly Automotive (ORLY) downgraded to Neutral from Overweight at Atlantic Equities with analyst Sam Hudson citing valuation and raised his price target to $400 from $370. 5. Maxar Technologies (MAXR) downgraded to Hold from Speculative Buy at TD Securities and to Underperformer from Neutral at CIBC. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
AZO AutoZone
$1,026.21

-18.305 (-1.75%)

05/22/19
WEDB
05/22/19
NO CHANGE
Target $1100
WEDB
Outperform
AutoZone price target raised to $1,100 from $1,030 at Wedbush
Wedbush analyst Seth Basham raised his price target for AutoZone to $1,100 from $1,030 after the company delivered Q3 results that beat expectations on the top- and bottom-lines. The analyst reiterates an Outperform rating on the shares.
04/23/19
FBCO
04/23/19
NO CHANGE
Target $1131
FBCO
Outperform
AutoZone price target raised to $1,131 from $1,050 at Credit Suisse
Credit Suisse analyst Seth Sigman raised his price target for AutoZone to $1,131 from $1,050 after hosting meetings with the company's management. The analyst notes that the team provided a positive view on the sector outlook, as well as the prospects for its commercial business based on a number of changes made over the last couple of years and the potential for less incremental expense growth in the out years after the step-up this year. Overall, Sigman came away confident in the company's ability to sustain recent sales/gross margin momentum, which combined with its discount valuation should support further outperformance. He reiterates an Outperform rating on the shares.
04/17/19
UBSW
04/17/19
NO CHANGE
Target $470
UBSW
Buy
O'Reilly Automotive, AutoZone price targets increased at UBS
UBS analyst Michael Lasser raised the price targets on his Buy-rated O'Reilly Automotive (ORLY) and AutoZone (AZO) to $470 and $1,210 from $415 and $1,065 respectively as part of his broader research note on auto repair shops. The analyst cites the findings of his bi-annual survey gauging sector demand, saying that some 69% of the shops surveyed saw sales volume as "at least flat" in March vs. the 66% who reported those figures last year. Lassar adds that while Q1 decelerated to 38% from 46%, about a third of the shops surveyed indicated that adverse weather hurt their business trends and the quarter was not indicative of the overall demand.
04/15/19
JPMS
04/15/19
NO CHANGE
Target $1126
JPMS
Overweight
AutoZone price target raised to $1,126 from $995 at JPMorgan
JPMorgan analyst Christopher Horvers raised his price target for AutoZone to $1,126 from $995 after hosting meetings with management. The company remains optimistic about sustained opportunities to grow its commercial program productivity toward the level of peers, Horvers tells investors in a research note. The analyst believes momentum in the sector remains intact and he expects AutoZone to have a strong finish to its current quarter. He keeps an Overweight rating on the shares.
PEI Pennsylvania REIT
$6.42

-0.005 (-0.08%)

05/06/19
BOSC
05/06/19
UPGRADE
BOSC
Outperform
Pennsylvania REIT upgraded to Outperform from Neutral at Boenning & Scattergood
12/19/18
JPMS
12/19/18
DOWNGRADE
Target $8
JPMS
Underweight
Pennsylvania REIT downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Anthony Paolone downgraded Pennsylvania REIT to Underweight and lowered his price target for the shares to $8 from $10. The downgrade is primarily driven by an improved outlook/preference for other property types in the REIT space, says the analyst.
12/20/18
BOSC
12/20/18
INITIATION
BOSC
Neutral
Pennsylvania REIT initiated with a Neutral at Boenning & Scattergood
Boenning & Scattergood analyst Merrill Ross initiated Pennsylvania REIT with a Neutral due to the highly leveraged balance sheet and vacancy risks.
HYG iShares iBoxx $ High Yield Corporate Bond
$84.94

-0.57 (-0.67%)

CAG Conagra Brands
$26.78

-0.09 (-0.33%)

05/20/19
MSCO
05/20/19
INITIATION
Target $31
MSCO
Equal Weight
Conagra Brands resumed with an Equal Weight at Morgan Stanley
Morgan Stanley analyst Pamela Kaufman resumed coverage of Conagra Brands with an Equal Weight rating and $31 price target. While she believes the company is well-positioned for revenue growth ahead of Packaged Food peers, she still sees risk with the turnaround of Pinnacle Foods and thinks the risk-reward appears balanced given recently rising expectations.
05/14/19
RHCO
05/14/19
INITIATION
Target $35
RHCO
Buy
Conagra Brands initiated with a Buy at SunTrust
SunTrust analyst William Chappell initiated Conagra Brands with a Buy rating and a price target of $35, saying the arrival of new management and its efforts to implement a "scalable, repeatable process" across the organization has led to growth in all of its business units. The analyst also sees signs of stabilization for packaged foods companies generally after a "challenging" few years amid a shift toward more favorable pricing and increased demographic tailwinds for frozen foods as more Millenials have children.
04/11/19
JPMS
04/11/19
NO CHANGE
Target $34
JPMS
Overweight
JPMorgan sees 'much more upside' in Conagra, boosts target to $34
JPMorgan analyst Ken Goldman raised his price target for Conagra Brands to $34 from $30 saying he sees "much more upside" in the shares. The company's longer-term sales guidance seems conservative and beatable, Goldman tells investors in a research note. He also believes management is addressing a number of investor concerns, including the sustainability of the frozen category's strength, the reasons for reductions in A&P spending, and the plan to turn around Pinnacle. Goldman reiterates an Overweight rating on Conagra Brands.
03/22/19
GSCO
03/22/19
NO CHANGE
Target $32
GSCO
Buy
Conagra Brands price target raised to $32 at Goldman Sachs after Q3 earnings
Goldman Sachs analyst Jason English nudged his price target on Conagra Brands higher to $32 from $31 and kept his Buy rating after its Q3 earnings beat, even though he sees the "quality" of the results as mixed. The analyst notes that the management succeeded in conveying to investors that earnings estimates "found a support level" while disproving concerns about the company's weakening core business. English further states that the company's unveiling of new Pinnacle Foods initiatives was sooner than he expected and believes that Conagra's earnings visibility has "improved materially", defusing the "uncertainty that lingered" after its Q2 guide-down.
ZYNE Zynerba
$12.35

-0.26 (-2.06%)

05/31/19
CANT
05/31/19
NO CHANGE
Target $22
CANT
Overweight
Zynerba price target raised to $22 from $12 at Cantor Fitzgerald
Cantor Fitzgerald analyst Charles Duncan raised his price target for Zynerba Pharmaceuticals to $22 from $12 citing his due diligence on Fragile X and the anecdotal use of CBD to alleviate symptoms for this and other pediatric orphan neurodevelopmental disorders. The analyst says he's also seen broadening interest in the medical cannabis space with the emergence of exchange traded funds possibly driving demand for the shares. Duncan reiterates an Overweight rating on Zynerba.
05/31/19
HCWC
05/31/19
NO CHANGE
Target $23
HCWC
Buy
Zynerba remains 'potentially dramatically undervalued,' says H.C. Wainwright
H.C. Wainwright analyst Oren Livnat says that even with the stock up 324% year-to-date, shares of Zynerba Pharmaceuticals remain "potentially dramatically undervalued." The analyst continues to entirely value the company on the opportunity in Fragile X Syndrome, and he expects Zynerba to soon announce CONNECT-FX Phase 3 enrollment completion which would put the company on track for transformative topline data in Q4. He projects peak U.S. sales of $700M and keeps a Buy rating on the shares with a $23 price target.
05/08/19
05/08/19
NO CHANGE

Zynerba reports Q1 EPS (47c), consensus (49c)
04/30/19
ROTH
04/30/19
INITIATION
Target $36
ROTH
Buy
Zynerba initiated with a Buy at Roth Capital
Roth Capital analyst Jerry Isaacson started Zynerba Pharmaceuticals with a Buy rating and $36 price target, telling investors that while the company's lead Fragile X Syndrome program is valuable, Zynerba's pipeline programs have more potential value. The next program in development is for developmental and epileptic encephalopathy, noted Isaacson, who values the potential of Zygel for the treatment of FXS at $5 per share and for DEE at $28 per share.

TODAY'S FREE FLY STORIES

03:05
10/14/19
10/14
03:05
10/14/19
03:05
General news
Asian Market Update: »

Asian Market Update:…

03:05
10/14/19
10/14
03:05
10/14/19
03:05
General news
FX Update: Currencies have opened the week in undramatic fashion »

FX Update: Currencies…

XLNX

Xilinx

$96.18

3.4 (3.66%)

, INTC

Intel

$52.06

0.95 (1.86%)

20:45
10/13/19
10/13
20:45
10/13/19
20:45
Upgrade
Xilinx, Intel rating change at Nomura Instinet »

Xilinx upgraded to Buy…

XLNX

Xilinx

$96.18

3.4 (3.66%)

INTC

Intel

$52.06

0.95 (1.86%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 24

    Oct

  • 20

    Nov

SFTBY

SoftBank

$0.00

(0.00%)

, SFTBF

SoftBank

$0.00

(0.00%)

19:49
10/13/19
10/13
19:49
10/13/19
19:49
Hot Stocks
Fly Intel: Top five weekend stock stories »

Catch up on the…

SFTBY

SoftBank

$0.00

(0.00%)

SFTBF

SoftBank

$0.00

(0.00%)

WE

We Company

$0.00

(0.00%)

FB

Facebook

$184.20

4.02 (2.23%)

BBBY

Bed Bath & Beyond

$12.98

0.89 (7.36%)

AMZN

Amazon.com

$1,730.79

11.115 (0.65%)

TGT

Target

$111.86

1.29 (1.17%)

T

AT&T

$37.58

0.17 (0.45%)

ITW

Illinois Tool Works

$154.56

4.68 (3.12%)

JNJ

Johnson & Johnson

$131.35

2.32 (1.80%)

NUE

Nucor

$52.69

2.48 (4.94%)

PNR

Pentair

$37.33

1.215 (3.36%)

GWW

Grainger

$305.24

16.49 (5.71%)

K

Kellogg

$62.14

-0.27 (-0.43%)

ATVI

Activision Blizzard

$54.80

1.1 (2.05%)

TTWO

Take-Two

$122.42

0.02 (0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 18

    Oct

  • 22

    Oct

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 25

    Oct

  • 27

    Oct

  • 28

    Oct

  • 29

    Oct

  • 29

    Oct

  • 29

    Oct

  • 30

    Oct

  • 06

    Nov

  • 07

    Nov

  • 07

    Nov

  • 13

    Nov

  • 19

    Nov

  • 21

    Nov

  • 21

    Nov

IGMS

IGM Biosciences

$17.53

-0.125 (-0.71%)

19:42
10/13/19
10/13
19:42
10/13/19
19:42
Initiation
IGM Biosciences initiated at Piper Jaffray »

IGM Biosciences initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LMAT

LeMaitre

$31.29

-0.03 (-0.10%)

19:37
10/13/19
10/13
19:37
10/13/19
19:37
Hot Stocks
LeMaitre acquires biologic patch business from Admedus »

LeMaitre Vascular…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

WE

We Company

$0.00

(0.00%)

, SFTBF

SoftBank

$0.00

(0.00%)

18:37
10/13/19
10/13
18:37
10/13/19
18:37
Periodicals
SoftBank seeking control of WeWork through financing package, WSJ says »

SoftBank (SFTBY) has…

WE

We Company

$0.00

(0.00%)

SFTBF

SoftBank

$0.00

(0.00%)

SFTBY

SoftBank

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

KOD

Kodiak Sciences

$18.24

1.34 (7.93%)

18:34
10/13/19
10/13
18:34
10/13/19
18:34
Hot Stocks
Kodiak Sciences announces safety, efficacy from Phase 1b study of KSI-301 »

Kodiak Sciences announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADVM

Adverum Biotechnologies

$5.29

0.11 (2.12%)

18:29
10/13/19
10/13
18:29
10/13/19
18:29
Recommendations
Adverum Biotechnologies analyst commentary at Piper Jaffray »

Adverum '022 looking…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADVM

Adverum Biotechnologies

$5.29

0.11 (2.12%)

18:23
10/13/19
10/13
18:23
10/13/19
18:23
Hot Stocks
Adverum Biotechnologies reports additional data from Phase 1 trial of ADVM-022 »

Adverum Biotechnologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COP

ConocoPhillips

$56.41

0.55 (0.98%)

18:03
10/13/19
10/13
18:03
10/13/19
18:03
Hot Stocks
ConocoPhillips announces $1.39B agreement to sell interests in Australia-West »

ConocoPhillips announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

T

AT&T

$37.58

0.17 (0.45%)

, CMCSA

Comcast

$45.53

1.02 (2.29%)

17:18
10/13/19
10/13
17:18
10/13/19
17:18
On The Fly
Box Office Battle: 'Joker' stays at number 1 with another $55M »

"Box Office Battle" is…

T

AT&T

$37.58

0.17 (0.45%)

CMCSA

Comcast

$45.53

1.02 (2.29%)

CMCSK

Comcast

$0.00

(0.00%)

SNE

Sony

$58.16

0.83 (1.45%)

LGF.A

Lionsgate

$9.52

0.22 (2.37%)

LGF.B

Lionsgate

$8.97

0.19 (2.16%)

DIS

Disney

$130.08

0.73 (0.56%)

VIAB

Viacom

$23.02

0.505 (2.24%)

VIA

Viacom

$25.45

0.65 (2.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 27

    Oct

  • 28

    Oct

  • 29

    Oct

  • 30

    Oct

  • 07

    Nov

  • 07

    Nov

  • 07

    Nov

  • 14

    Nov

  • 14

    Nov

  • 19

    Nov

PCG

PG&E

$8.08

0.3 (3.86%)

16:48
10/13/19
10/13
16:48
10/13/19
16:48
Periodicals
PG&E turns down San Francisco's $2.5B offer to acquire assets, Reuters says »

PG&E rejected a $2.5B…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Nov

  • 10

    Nov

  • 12

    Nov

  • 07

    Jan

TTGT

TechTarget

$22.64

0.14 (0.62%)

, SKHCY

Sonic Healthcare

$0.00

(0.00%)

16:44
10/13/19
10/13
16:44
10/13/19
16:44
Conference/Events
Commvault to hold a conference »

Commvault GO 2019 will be…

TTGT

TechTarget

$22.64

0.14 (0.62%)

SKHCY

Sonic Healthcare

$0.00

(0.00%)

NTAP

NetApp

$51.50

1.74 (3.50%)

HPE

HP Enterprise

$14.35

0.24 (1.70%)

HLF

Herbalife Nutrition

$39.07

0.51 (1.32%)

FORR

Forrester

$32.43

0.61 (1.92%)

CSCO

Cisco

$46.52

0.38 (0.82%)

CVLT

Commvault

$45.51

0.695 (1.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Oct

  • 23

    Oct

  • 29

    Oct

  • 29

    Oct

  • 06

    Nov

  • 12

    Nov

  • 13

    Nov

  • 12

    Dec

FB

Facebook

$184.20

4.02 (2.23%)

16:43
10/13/19
10/13
16:43
10/13/19
16:43
Periodicals
Warren buying Facebook ads claiming Zuckerberg backs Trump, Bloomberg says »

Elizabeth Warren is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

  • 30

    Oct

KBH

KB Home

$33.92

-0.15 (-0.44%)

16:43
10/13/19
10/13
16:43
10/13/19
16:43
Conference/Events
SunTrust to hold a field trip »

Field Trip with KB Homes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Oct

BX

Blackstone

$47.10

0.62 (1.33%)

16:34
10/13/19
10/13
16:34
10/13/19
16:34
Periodicals
Blackstone discussed with Citadel about buying stake, WSJ reports »

Blackstone has held talks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

GOOG

Alphabet

$1,213.86

5.88 (0.49%)

, GOOGL

Alphabet Class A

$1,214.62

6.18 (0.51%)

16:29
10/13/19
10/13
16:29
10/13/19
16:29
Periodicals
Google bars high-interest consumer loan services from app store, WSJ reports »

Google has barred…

GOOG

Alphabet

$1,213.86

5.88 (0.49%)

GOOGL

Alphabet Class A

$1,214.62

6.18 (0.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

  • 28

    Oct

  • 28

    Oct

  • 29

    Oct

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$296.34

3.1 (1.06%)

16:28
10/13/19
10/13
16:28
10/13/19
16:28
General news
Trump working with Congress on 'powerful' Turkey sanctions »

President Trump tweeted…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$296.34

3.1 (1.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGN

Allergan

$169.06

1.255 (0.75%)

16:23
10/13/19
10/13
16:23
10/13/19
16:23
Hot Stocks
Allergan, Molecular Partners present data from Phase 3 Abicipar pegol studies »

Allergan and Molecular…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LYFT

Lyft

$39.49

1.8 (4.78%)

, UBER

Uber

$30.09

1.19 (4.12%)

16:04
10/13/19
10/13
16:04
10/13/19
16:04
Periodicals
Lyft sues NYC over cruising time caps, Reuters reports »

Following its rival…

LYFT

Lyft

$39.49

1.8 (4.78%)

UBER

Uber

$30.09

1.19 (4.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 04

    Nov

  • 07

    Nov

  • 19

    Nov

GM

General Motors

$35.57

0.9 (2.60%)

15:59
10/13/19
10/13
15:59
10/13/19
15:59
Periodicals
UAW boosting strike pay as General Motor walkout continues, Reuters says »

The United Auto Workers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

MRK

Merck

$84.31

0.6 (0.72%)

, JNJ

Johnson & Johnson

$131.35

2.32 (1.80%)

15:49
10/13/19
10/13
15:49
10/13/19
15:49
Periodicals
Congo to start using Johnson & Johnson Ebola vaccine next month, Reuters says »

Health authorities in…

MRK

Merck

$84.31

0.6 (0.72%)

JNJ

Johnson & Johnson

$131.35

2.32 (1.80%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 23

    Oct

  • 29

    Oct

  • 06

    Nov

  • 24

    Jan

  • 24

    Jan

  • 14

    Mar

HMTV

Hemisphere Media

$11.70

0.05 (0.43%)

15:48
10/13/19
10/13
15:48
10/13/19
15:48
Initiation
Hemisphere Media initiated at Wells Fargo »

Hemisphere Media…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFE

Pfizer

$36.11

0.31 (0.87%)

15:37
10/13/19
10/13
15:37
10/13/19
15:37
Hot Stocks
Pfizer presents Phase 3 data for Abrocitinib in moderate to severe AD »

Pfizer announced complete…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 06

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.